Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
2
33%
Ph phase_3
1
17%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(2)
Terminated(2)
Other(2)

Detailed Status

Completed2
Terminated2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

completed233%
terminated233%
unknown233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_3

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

NCT05557942
terminatedphase_2

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

NCT05036135
unknownphase_1

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

NCT05280054
unknownphase_2

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

NCT04147949
completedphase_2

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

NCT03078322
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05557942Phase 3

Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Terminated
NCT05036135Phase 2

A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
NCT05280054Phase 1

AV-101 Alone and in Combination With Probenecid in Healthy Subjects

Unknown
NCT04147949Phase 2

AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Unknown
NCT03078322Phase 2

AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

Completed
NCT01483846Phase 1

Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6